Filing Analysis
Actuate Therapeutics, Inc. reported the voting results from its virtual Annual Meeting of Stockholders held on May 21, 2026. Stockholders elected two Class II directors to serve three-year terms and ratified the appointment of Crowe LLP as the company's independent registered public accounting firm for 2026.
📋 Key Facts
- The Annual Meeting of Stockholders was held virtually on May 21, 2026.
- Stockholders elected Aaron G.L. Fletcher, Ph.D. (14,877,247 votes For) and Jason Keyes (16,727,875 votes For) as Class II directors to serve until the 2029 Annual Meeting.
- Stockholders ratified the appointment of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 18,571,817 votes For, 50,023 votes Against, and 9,741 abstentions.
Actuate Therapeutics announced FDA clearance of an Investigational New Drug (IND) application for its lead candidate, elraglusib, to proceed with a Phase 1/2 study. The company also released an updated corporate presentation outlining its future development plans.
📋 Key Facts
- FDA cleared the IND application for elraglusib on May 11, 2026.
- The clearance allows the company to initiate a Phase 1/2 clinical study.
- The company furnished a new corporate presentation as Exhibit 99.2.
- Actuate Therapeutics is an emerging growth company listed on the Nasdaq Stock Market.
Actuate Therapeutics expanded its board to eight members and appointed Dr. Martin H. Huber, a veteran oncology executive, as a Class III director. Dr. Huber will also provide research and development advisory services under a separate consulting agreement.
🚩 Red Flags
- Potential related-party conflict: The director is receiving additional consulting fees ($12,000/year) beyond standard board compensation.
📋 Key Facts
- Appointed Martin H. Huber, MD, to the Board of Directors effective May 1, 2026.
- Board expanded from seven to eight members to accommodate the new appointment.
- Dr. Huber will receive an annual retainer of $44,000 and an initial grant of 30,000 stock options vesting over three years.
- Entered into a consulting agreement with Dr. Huber for R&D advisory services at $3,000 per quarter.
- Dr. Huber previously served as CEO of Mersana Therapeutics and CMO of TESARO (acquired by GSK).